Azopt is a brand name for the topical ocular medication brimonidine tartrate. It is classified as an a2-adrenergic agonist used to lower intraocular pressure in glaucoma patients. The active ingredient reduces the production of aqueous humor by decreasing the activity of ciliary epithelial cells. By enhancing outflow of fluid from the eye, it modestly lowers the pressure inside the globe. This occurs through binding to a2-adrenergic receptors on the ciliary body and trabecular meshwork. The decreased aqueous humor volume leads to improved drainage and reduced ocular tension. The effect is reversible and achieved within hours after administration of each drop. Clinically, Azopt helps maintain normal eye pressure when used regularly as part of glaucoma therapy.

Azopt is a prescription eye drop that reduces intraocular pressure in patients with glaucoma or ocular hypertension. It belongs to the class of carbonic anhydrase inhibitors which block the enzyme carbonic anhydrase in the eye. By inhibiting this enzyme the medication decreases the production of aqueous humor inside the eye. The reduction in fluid pressure helps the optic nerve stay protected from damage. This mechanism provides a direct therapeutic effect for managing elevated eye pressure. The drug is administered as a topical solution that is absorbed through the cornea. Its active ingredient travels to the cells that secrete fluid to suppress excess secretion. Overall Azopt offers a targeted approach to controlling intraocular pressure without systemic impact.

The most common side effects reported in trials include headache, nausea, and mild fatigue. Headache often appears early and may vary in intensity. Nausea is typically mild and tends to decrease with continued use. Fatigue is described as a general sense of tiredness without specific physical limitation. Some participants note a sensation of mild dizziness during the first few days. Skin reactions such as slight itching or warmth are occasionally observed. These effects are generally transient and resolve without intervention. Most individuals experience only one or two of these symptoms concurrently.

The most common side effects often include mild headache, fatigue, and temporary soreness at the injection site. These reactions are usually short-lived and resolve without intervention. Some individuals may experience low-grade fever or chills that last a day or two. Mild nausea and muscle aches are also reported in a small percentage of cases. Most of these effects are not severe and do not require medical attention. They tend to be more frequent after the second dose of a multi-dose series. The prevalence of each symptom varies by age group and vaccine type. Overall, the side effects are generally predictable and part of the expected immune response.